TD Cowen initiated coverage of BrightSpring Health (BTSG) with a Buy rating and $37 price target The company, a leading oncology-focused specialty pharmacy and home health provider, is positioned to benefit from continued specialty growth and a generic wave driven by pharma’s upcoming patent cliff, the analyst tells investors in a research note. The firm says its price target implies the shares trade at 15-times its adjusted EBITDA estimate for fiscal 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services Executive Resignation Announced
- BrightSpring Health Services: Strong Growth Potential in Specialty and Infusion Pharmacy Sectors
- BrightSpring Health Services, Inc.: Strong Growth Prospects and Strategic Investments Justify Buy Rating
- BrightSpring Health Services Stock Offering Agreement
- BrightSpring Health 14M share Spot Secondary priced at $21.75